Global consumption patterns of combination hypertension medication: An analysis of pharmaceutical sales data from 2010-2021.

Hypertension is the most significant risk factor for cardiovascular disease and mortality worldwide, affecting 1.3 billion adults. Global disparities in hypertension control are widening with low- and middle-income countries (LMIC) having the fastest growing rates of hypertension and low rates of control.

The global impact of COVID-19 on drug purchases: A cross-sectional time series analysis.

Background: The drug supply chain is global and at risk of disruption and subsequent drug shortages, especially during unanticipated events.

Objective: Our objective was to determine the impact of coronavirus disease 2019 (COVID-19) on drug purchases overall, by class, and for specific countries.

Methods: A cross-sectional time series analysis of country-level drug purchase data from August 2014 to August 2020 from IQVIA MIDAS was conducted.

Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study.

Background: Opioid analgesics play a key role in pain management but providing access while mitigating risk of misuse and dependence remains a challenge. Tracking global consumption of all opioids over time can help identify emerging patterns and drivers of use.

Methods: Prescription opioid analgesic consumption was estimated for 76 countries between 2009 and 2019 using IQVIA MIDAS data.

Health spending expenditures for commercial plans are predominantly concentrated among a small population of high-intensity consumers across settings of care.

Rising health care spending has sparked new efforts to constrain health care expenditures. To explore how health care spending is distributed across consumers and how utilization patterns compare across health care resource expenditures (eg, hospital, outpatient care). Using the IQVIA PharMetrics Plus database, we conducted a retrospective claims analysis for the 2018 plan year to examine commercial health care spending and utilization across 5 settings of care: ambulatory services, inpatient services, office visits, pharmacy services, and additional services.

Patterns of dental antibiotic prescribing in 2017: Australia, England, United States, and British Columbia (Canada).

Objective: Our objective was to compare patterns of dental antibiotic prescribing in Australia, England, and North America (United States and British Columbia, Canada).

Design: Population-level analysis of antibiotic prescription.

Setting: Outpatient prescribing by dentists in 2017.

Characteristics Associated With Opioid and Antibiotic Prescribing by Dentists.

Introduction: The objective of this study is to identify county-level characteristics that may be high-impact targets for opioid and antibiotic interventions to improve dental prescribing.

Methods: Prescriptions during 2012-2017 were extracted from the IQVIA Longitudinal Prescription database. Primary outcomes were yearly county-level antibiotic and opioid prescribing rates.

Author Correction: Time-lapse imagery and volunteer classifications from the Zooniverse Penguin Watch project.

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Time-lapse imagery and volunteer classifications from the Zooniverse Penguin Watch project.

Automated time-lapse cameras can facilitate reliable and consistent monitoring of wild animal populations. In this report, data from 73,802 images taken by 15 different Penguin Watch cameras are presented, capturing the dynamics of penguin (Spheniscidae; Pygoscelis spp.) breeding colonies across the Antarctic Peninsula, South Shetland Islands and South Georgia (03/2012 to 01/2014).

Unexplored therapeutic opportunities in the human genome.

This corrects the article DOI: 10.1038/nrd.2018.

Unexplored therapeutic opportunities in the human genome.

A large proportion of biomedical research and the development of therapeutics is focused on a small fraction of the human genome. In a strategic effort to map the knowledge gaps around proteins encoded by the human genome and to promote the exploration of currently understudied, but potentially druggable, proteins, the US National Institutes of Health launched the Illuminating the Druggable Genome (IDG) initiative in 2014. In this article, we discuss how the systematic collection and processing of a wide array of genomic, proteomic, chemical and disease-related resource data by the IDG Knowledge Management Center have enabled the development of evidence-based criteria for tracking the target development level (TDL) of human proteins, which indicates a substantial knowledge deficit for approximately one out of three proteins in the human proteome.